期刊
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 85, 期 10, 页码 2198-2204出版社
WILEY
DOI: 10.1111/bcp.13979
关键词
body surface area; cancer; dose-response; flat dosing; log-dose; surrogate outcome
Drug development for cancer chemotherapy has an interesting history. A mix of serendipity, animal, cell line, and standard pharmacological principles of dose, dose-response, dose-concentration, dose intensity and combination therapies have been used to develop optimal dosing schedules. However in practice, significant gaps in the translation of preclinical to clinical dosing schedules persist, and clinical development has instead moved to new drug development. A older chemotherapies are still the backbone of most solid tumour schedules, therapeutic drug monitoring has emerged as a method for optimising the dose for individual patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据